Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 3,335 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control label Clear all
Active, not recruiting Phase 2 Interventional

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

NCT06653842
View directory record Official record
Conditions
Cutaneous Venous Malformations
Interventions
QTORIN 3.9% rapamycin anhydrous gel
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Irvine, California • Palo Alto, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

NCT03526861
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebos
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 21, 2026, 10:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Venous Endothelial Cells in Rheumatoid Arthritis

NCT02468986
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

NCT03110562
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Bortezomib, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
20
States / cities
Plantation, Florida • Atlanta, Georgia • Honolulu, Hawaii + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of a Flu Vaccine in Children

NCT00001127
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (CAIV-T)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Months to 18 Years
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 21, 2026, 10:30 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

NCT02683941
View directory record Official record
Conditions
Neuroendocrine Tumors in Lung
Interventions
Lanreotide (Autogel formulation), Placebo, Best Supportive Care
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 21, 2026, 10:30 PM EDT
Terminated Phase 2Phase 3 Interventional

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy

NCT05747794
View directory record Official record
Conditions
Breast Carcinoma
Interventions
eftilagimod alpha, Paclitaxel, placebo
Biological · Drug · Other
Lead sponsor
Immutep S.A.S.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Whittier, California • Washington D.C., District of Columbia • Rock Hill, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer

NCT01686256
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer
Interventions
Tc 99m EC20
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Studying the Impact of Product Packaging in a Virtual Store Environment

NCT04381481
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Experimental Drink: Nutrition claim on fruit drinks, Control Drink: No nutrition claim, Experimental snack: Text warning, Experimental snack: Graphic warning, Control snack: barcode label
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
2,374 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 21, 2026, 10:30 PM EDT
Terminated Phase 3 Interventional

RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

NCT03699956
View directory record Official record
Conditions
Carcinoma, Small Cell Lung
Interventions
RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide
Combination Product · Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Denver, Colorado • Orange City, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

NCT02558231
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan, Tadalafil, Selexipag
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
20
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 21, 2026, 10:30 PM EDT
Not listed Phase 4 Interventional

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCT06093451
View directory record Official record
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation

NCT01614470
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 21, 2026, 10:30 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study of AT132 in Young Children With X-Linked Myotubular Myopathy (XLMTM)

NCT03199469
View directory record Official record
Conditions
X-Linked Myotubular Myopathy
Interventions
Resamirigene bilparvovec
Genetic
Lead sponsor
Astellas Gene Therapies
Industry
Eligibility
Up to 5 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects

NCT00618839
View directory record Official record
Conditions
Third Degree Burn, Burns, Wound Infection, Degloving Injury
Interventions
StrataGraft Skin Tissue, Cadaver allograft
Biological · Procedure
Lead sponsor
Stratatech, a Mallinckrodt Company
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Phoenix, Arizona • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 21, 2026, 10:30 PM EDT
Not listed Not applicable Interventional

PoNS Clinical Experience Program (TBI)

NCT03882554
View directory record Official record
Conditions
Mild to Moderate Traumatic Brain Injury
Interventions
PoNS Treatment
Device
Lead sponsor
Helius Medical Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 21, 2026, 10:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia

NCT03715972
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Healthy Controls
Interventions
Hydroxyurea, Acetazolamide
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
7 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 1 Interventional

Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

NCT02431312
View directory record Official record
Conditions
Hepatitis B
Interventions
INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment
Biological · Drug
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Manhasset, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 21, 2026, 10:30 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess the Efficacy and Safety of Raxone in LHON Patients

NCT02774005
View directory record Official record
Conditions
Leber's Hereditary Optic Neuropathy (LHON)
Interventions
Idebenone
Drug
Lead sponsor
Santhera Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
9
States / cities
Phoenix, Arizona • Palo Alto, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 21, 2026, 10:30 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

NCT02082522
View directory record Official record
Conditions
Hilar Cholangiocarcinoma
Interventions
Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen
Drug · Procedure
Lead sponsor
Concordia Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 21, 2026, 10:30 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4515100 in Healthy Participants

NCT07339722
View directory record Official record
Conditions
Healthy
Interventions
LY4515100 via SAD, LY4515100 via MAD, LY4515100, Itraconazole, Caffeine, Digoxin, Iohexol, Metformin, Rosuvastatin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 21, 2026, 10:30 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

NCT04777331
View directory record Official record
Conditions
Parkinsons Disease
Interventions
Prasinezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 10:30 PM EDT
Terminated Phase 2 Interventional Results available

Weight-based Dosing in Hemophilia A

NCT02586012
View directory record Official record
Conditions
Hemophilia
Interventions
rFVIII
Drug
Lead sponsor
Craig Seaman
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 21, 2026, 10:30 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

NCT05654922
View directory record Official record
Conditions
Pre-Bronchiolitis Obliterans Syndrome
Interventions
ARINA-1, Standard of care only
Drug · Other
Lead sponsor
Renovion, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 21, 2026, 10:30 PM EDT